Westminster, CA – September 2, 2021 – BioLargo, Inc.
(OTCQB:BLGO), a developer of sustainable cleantech technologies and
full-service environmental engineering company, announced that it has launched a
new service offering to test customer water to determine PFAS contamination
levels and advise on appropriate treatment equipment options to meet federal,
state and local regulatory requirements. The program offers peace of mind and
proof of concept to customers who need PFAS water treatment solutions in the
face of an uncertain and rapidly evolving technological and regulatory
landscape.
Per- and polyfluoroalkyl substances (PFAS) are man-made
chemicals that contaminate drinking water in thousands of sites in the United States.
The Federal government, and many state governments, are tightening regulations due
to mounting evidence about the impacts of PFAS chemicals on human health and
their ubiquity in water throughout the developed world. Learn more at
https://www.biolargoengineering.com/biolargo-answers-administrations-urgent-call-for-mitigation-of-pfas-forever-chemicals/.
BioLargo’s new PFAS Testing Program offers customers timely,
accurate, and reliable testing of their water to determine, quantify, and qualify
their PFAS contamination problem. Once contamination and water chemistry are
characterized, BioLargo selects and optimizes appropriate water treatment equipment
from a menu of different technologies that addresses the customer’s specific
water chemistry and PFAS contamination makeup. The company then offers on-site
piloting of the company’s own PFAS water treatment technology (the Aqueous
Electrostatic Concentrator, or AEC). The AEC is a low-cost,
low-waste, and sustainable solution for removing PFAS from water.
Customers can reach out to BioLargo engineers to schedule
testing at https://www.biolargoengineering.com/biolargo-pfas-testing-program/.
Randall Moore, President of BioLargo’s engineering division
said, “With the launch of this new program, our engineers will be able to
better serve municipalities that are struggling with having to close water
wells due to PFAS contamination. Our AEC system reduces treatment costs because
it generates only a fraction of the PFAS-laden waste compared to other
treatment technologies like carbon filtration or ion exchange. No two water
sources have the same underlying chemistry, and there are over 4,500 different
PFAS compounds that can contaminate water. Thus, it is crucial to optimize
treatment processes for each situation.”
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) invents, develops, and
commercializes innovative platform technologies to solve challenging
environmental problems like PFAS contamination, advanced water and wastewater
treatment, industrial odor and VOC control, air quality control, and infection
control. With over 13 years of extensive R&D, BioLargo holds a wide array
of issued patents, maintains a robust pipeline of products, and provides
full-service environmental engineering. Our peer-reviewed scientific approach
allows us to invent or acquire novel technologies and develop them to maturity
through our operating subsidiaries. With a keen emphasis on collaborations with
academic, municipal, and commercial organizations and associations, BioLargo
has proven itself with over 80 awarded grants and numerous pilot projects. We
monetize through direct sales, recurring service contracts, licensing
agreements, strategic joint venture formation and/or the sale of the IP. See
our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include without limitation those about
BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19
pandemic; anticipated revenue; and plans for future operations. These
statements involve risks and uncertainties, and actual results may differ
materially from any future results expressed or implied by the forward-looking
statements. Risks and uncertainties include without limitation: the effect of
the COVID-19 pandemic on the Company’s business, results of operations,
financial condition, and stock price; the effect of regional economic
conditions on the Company’s business, including effects on purchasing decisions
by consumers and businesses; the ability of the Company to compete in markets
that are highly competitive and subject to rapid technological change; the
ability of the Company to manage frequent introductions and transitions of
products and services, including delivering to the marketplace, and stimulating
customer demand for, new products, services, and technological innovations on a
timely basis; the dependency of the Company on the performance of distributors
of the Company’s products. More information on these risks and other potential
factors that could affect the Company’s business and financial results is
included in the Company’s filings with the SEC, including in the “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic reports on
Form 10-K and Form 10-Q and subsequent filings. The Company assumes no
obligation to update any forward-looking statements or information, which speak
as of their respective dates.
